Securities Code: 002412 Securities Abbreviation: Hansen Pharmaceutical Announcement No.: 2026-008 Hunan Hansen Pharmaceutical Co., Ltd. Announcement on the 2026 Salary and Remuneration Plan for Directors and Senior Management The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
Hunan Hansen Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), in accordance with the "Company Law," "Corporate Governance Guidelines for Listed Companies," "Articles of Association," "Rules of Procedure for the Remuneration and Assessment Committee," and other relevant regulations, and in conjunction with the current economic environment, the Company's location, industry, and scale, and by referencing industry remuneration levels, has formulated the 2026 Salary and Remuneration Plan for Directors and Senior Management. On April 24, 2026, the Company held the eleventh meeting of the sixth Board of Directors, which deliberated on the "Proposal on Formulating the 2026 Salary and Remuneration Plan for Directors and Senior Management." As the remuneration plan involves all directors, all directors abstained from voting, and this plan will be directly submitted to the Company's 2025 Annual General Meeting for deliberation. The relevant matters are hereby announced as follows:
I. Target Audience This plan applies to the Company's directors (including independent directors and non-independent directors) and senior management.